Inhaled interventions in cystic fibrosis: Mucoactive and antibiotic therapies

Respiration

Volumn 88, Issue 6, 2014, Pages 441-448

  Hurt, Katharine ^a   Bilton, Diana ^b,c  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Cystic fibrosis; Hyperosmolar therapy; Inhaled antibiotics; Mucolytic therapy

Indexed keywords

ANTIBIOTIC AGENT; MANNITOL; MUCOLYTIC AGENT; ANTIINFECTIVE AGENT; EXPECTORANT AGENT; RESPIRATORY TRACT AGENT;

ANTIBIOTIC THERAPY; ARTICLE; CYSTIC FIBROSIS; DISEASE EXACERBATION; DRY POWDER INHALER; HUMAN; LONG TERM CARE; LUNG FIBROSIS; LUNG FUNCTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MUCOCILIARY CLEARANCE; MUCOLYSIS; OBSTRUCTIVE AIRWAY DISEASE; PATIENT SATISFACTION; PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL (TOPIC); COMPLICATION; DRUG EFFECTS; FEMALE; INHALATIONAL DRUG ADMINISTRATION; LUNG DISEASES; MALE; PATHOPHYSIOLOGY; PROGNOSIS; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; EXPECTORANTS; FEMALE; HUMANS; LUNG DISEASES; MALE; MUCOCILIARY CLEARANCE; PROGNOSIS; RESPIRATORY SYSTEM AGENTS; TREATMENT OUTCOME;

EID: 84917708750     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000369533     Document Type: Article

References (41)

1. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989; 245: 1066-1073
2. Zhou Z, Duerr J, Johannesson B, et al. The βENaC-overexpressing mouse as a model of cystic fibrosis lung disease. J Cyst Fibros 2011; 10:S172-S182
3. Hoegger MJ, Fischer AJ, McMenimen JD, et al. Impaired mucus detachment disrupts mucociliary transport in a piglet model of cystic fibrosis. Science 2014; 345: 818
4. Sly PD, Gangell CL, Chen L, et al. Risk factors for bronchiectasis in children with cystic fibrosis. N Engl J Med 2013; 368: 1963-1970
5. Shak S. Aerosolised recombinant human DNase 1 for the treatment of cystic fibrosis. Chest 1995; 107: 65S-70S.
6. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994; 331: 637-642
7. Paul K, Rietschel E, Ballmann M, et al. Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis. Am J Respir Crit Care Med 2004; 169: 719-725
8. Jones AP, Wallis C. Dornase alfa for cystic fibrosis. Cochrane Database Syst Rev 2010; 3:CD001127
9. George PM, Banya W, Pareek N, et al. Improved survival at low lung function in cystic fibrosis: cohort study from 1990-2007. BMJ 2011; 342: 1008
10. Heijerman H, Westerman E, Conway S, et al. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus. J Cyst Fibros 2009; 8: 295-315
11. Mogayzel PJ, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2013; 187: 680-689
12. Berge MT, Van Der Weil E, Tiddens HA, et al. DNase in stable cystic fibrosis infants. J Cyst Fibros 2003; 2: 183-188
13. Van Der Giessen L. Does the timing of inhaled dornase alfa matter?. J Cyst Fibros 2009; 8:S6-S9
14. Shak S, Capon DJ, Hellmiss R, et al. Recombinant human DNase 1 reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci USA 1990; 87: 9188-9192
15. Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006; 354: 229-240
16. Michon A-L, Jumas-Bilak E, Chiron R, et al. Advances toward the elucidation of hypertonic saline effects on Pseudomonas aeruginosa from cystic fibrosis patients. PLoS One 2014; 9:e90184
17. Dwyer T, Elkins M, Dentice R, et al. Saline at lower tonicity in cystic fibrosis (SALTI-CF) trial: a randomised controlled trial comparing 0.9% vs. 3% vs. 6% nebulised saline. J Cyst Fibros 2013; 12:S19
18. Rowe RC, Sheskey PJ, Weller PJ (eds): Handbook of Pharmaceutical Excipients. Chicago, Pharmaceutical Press, 2003
19. Daviskas E, Anderson SD, Brannan JD, et al. Inhalation of dry powder mannitol increases mucociliary clearance. Eur Respir J 1997; 10: 2449-2454
20. Robinson M, Daviskas E, Ebert S, et al. The effect of inhaled mannitol on bronchial mucus clearance in CF patients: a pilot study. Eur Respir J 1999; 14: 678-685
21. Hurt K, Bilton D. Inhaled mannitol for the treatment of cystic fibrosis. Expert Rev Respir Med 2012; 6: 19-26
22. Teper A, Jaques A, Charlton B. Inhaled mannitol in patients with cystic fibrosis: a randomised open label dose response trial. J Cyst Fibros 2011; 10: 1-8
23. Jaques AJ, Daviskas E, Turton JA, et al. Inhaled mannitol improves lung function in cystic fibrosis. Chest 2008; 133: 1388-1396
24. Bilton D, Robinson P, Cooper P, et al. Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study. Eur Respir J 2011; 38: 1071-1080
25. Aitken ML, Bellon G, De Boeck K, et al. Long term inhaled dry powder mannitol in cystic fibrosis: an international randomised study. Am J Respir Crit Care Med 2012; 185: 645-652
26. Bilton D, Bellon G, Charlton B, et al. Pooled analysis of two large randomised phase 3 inhaled mannitol studies in cystic fibrosis. J Cyst Fibros 2013; 12: 367-376
27. Sawicki GS, Sellers DE, Robinson WM. High treatment burden in adults with cystic fibrosis: challenges to disease self-management. J Cyst Fibros 2009; 8: 91-96
28. George PM, Banya W, Pareek N, et al. Improved survival at low lung function in cystic fibrosis: cohort study from 1990 to 2007. BMJ 2011; 342:d1008
29. Hodson ME, Penketh AR, Batten JC. Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis. Lancet 1981; 2: 1137-1139
30. Jensen T, Pedersen SS, Garne S, Heilmann C, Hoiby N, Koch C. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection. J Antimicrob Chemother 1987; 19: 831-838
31. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev-K M, Borowitz D, Bowman CM, Marshall BC, Marshall S, Smith AL. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999; 340: 23-30
32. McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, Montgomery AB. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008; 178: 921-928
33. Assael BM, Pressler T, Bilton D, Fayon M, Fischer R, Chiron R, LaRosa M, Knoop C, McElvaney N, Lewis SA, Bresnik M, Montgomery AB, Oermann CM, AZLI Active Comparator Study Group: Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial. J Cyst Fibros 2013; 12: 130-140
34. Lo D, VanDevanter DR, Flume P, Smyth A. Aerosolized antibiotic therapy for chronic cystic fibrosis airway infections: continuous or intermittent?. Respir Med 2011; 105(suppl 2):S9-S17
35. Bakker EM, Volpi S, Salonini E, et al. Improved treatment response to dornase alfa in cystic fibrosis patients using controlled inhalation. Eur Respir J 2011; 38: 1328-1335
36. Daniels T, Goodacre L, Sutton C, Pollard K, Conway S, Peckham D. Accurate assessment of adherence: self-report and clinician report vs. electronic monitoring of nebulizers. Chest 2011; 140: 425-432
37. Geller DE, Weers J, Heuerding S. Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere TM technology. J Aerosol Med Pulm Drug Deliv 2011; 24: 175-182
38. Konstan MW, Flume PA, Kappler M, Chiron R, Higgins M, Brockhaus F, Zhang J, Angyalosi G, He E, Geller DE. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial. J Cyst Fibros 2011; 10: 54-61
39. Geller DE, Nasr SZ, Piggott S, He E, Angyalosi G, Higgins M. Tobramycin inhalation powder in cystic fibrosis patients: response by age group. Respir Care 2014; 59: 388-398
40. Schuster A, Haliburn C, Doring G, Goldman MH, Freedom Study Group: Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study. Thorax 2013; 68: 344-350
41. Cystic Fibrosis Trust: UK cystic fibrosis registry annual data report 2013. http://www.cysticfibrosis. org.uk/media/598466/annual-data-report-2013-jul14.pdf